Using data from drug discovery and development to aid the aquatic environmental risk assessment of human pharmaceuticals: Concepts, considerations, and challenges

Integrated Environmental Assessment and Management

Volumn 6, Issue 1, 2010, Pages 38-51

  Winter, Matthew J ^a   Owen, Stewart F ^a   Murray Smith, Richard ^b   Panter, Grace H ^a   Hetheridge, Malcolm J ^a   Kinter, Lewis B ^a  

^a ASTRAZENECA   (United Kingdom)

^b Safety Assessment US ^*

Author keywords

Environmental risk assessment; ERA; MoA; Pharmaceuticals in the environment; Read across

Indexed keywords

DRUG;

CONFERENCE PAPER; DRUG DEVELOPMENT; ENVIRONMENTAL MONITORING; HUMAN; METHODOLOGY; RISK ASSESSMENT;

DRUG DISCOVERY; ENVIRONMENTAL MONITORING; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 77249106180     PISSN: 15513793     EISSN: None     Source Type: Journal    
DOI: 10.1897/IEAM_2009-044.1     Document Type: Conference Paper

References (86)

1. Ankley GT, Black MC, Garric J, Hutchinson TH, Iguchi T. 2005. A framework for assessing the hazard of pharmaceutical materials to aquatic species. In: Williams RT, editor. Human pharmaceuticals: Assessing the impact on aquatic ecosystems. Pensacola (FL): SETAC. p 183-237.
2. Ankley GT, Brooks BW, Huggett DB, Sumpter JP. 2007. Repeating history: pharmaceuticals in the environment. Environ Sci Technol 41:8211-8217.
3. Ashton D, HiltonM, Thomas KV. 2004. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 333:167-184.
4. Barnes KK, Kolpin DW, Furlong ET, Zaugg SD, Meyer MT, Barber L. 2008. A national reconnaissance of pharmaceuticals and other organic wastewater contaminants in the United States-I. Groundwater. Sci Total Environ 402: 192-200.
5. Benson WH, Gallagher K, McClintock JT. 2007. U.S. environmental protection agency's activities to prepare for regulatory and risk assessment applications of genomics information. Environ Mol Mutagen 48:359-362.
6. Bergese P, Cretich M, Oldani C, Oliviero G, Di Carlo G, Depero LE, Chiari M. 2008. Advances in parallel screening of drug candidates. Curr Med Chem 15:1706-1719.
7. Besse J-P, Garric J. 2008. Human pharmaceuticals in surface waters: implementation of a prioritization methodology and application to the French situation. Toxicol Lett 176:104-123.
8. Bound JP, Voulvoulis N. 2005. Household disposal of pharmaceuticals as a pathway for aquatic contamination in the United kingdom. Environ Health Perspect 113:1705-1711. (Pubitemid 41794265)
9. Caprino L. 1990. Evaluation of drug safety by toxicological test procedures as provided by regulatory laws: an overview. Pharmacol Res 22:253-262.
10. Collins TF. 2006. History and evolution of reproductive and developmental toxicology guidelines. Curr Pharm Des 12:449-1465.
11. Cunningham VL. 2004. Special characteristics of pharmaceuticals related to environmental fate. In: Kümmerer K, editor. Pharmaceuticals in the environment: Sources, fate, effects and risks. 2nd ed. Berlin (DE): Springer- Verlag. p 13-24.
12. Dahlström M, Lindgren F, Berntsson K, Sjögren M, Mårtensson LG, Jonsson PR, Elwing H. 2005. Evidence for different pharmacological targets for imidazoline compounds inhibiting settlement of the barnacle Balanus improvisus. J Exp Zool A Comp Exp Biol 303:551-562.
13. Dahms HU, Jin T, Qian PY. 2004. Adrenoceptor compounds prevent the settlement of marine invertebrate larvae: Balanus amphitrite (Cirripedia), Bugula neritina (Bryozoa) and Hydroides elegans (Polychaeta). Biofouling 20:313-321.
14. Delistraty D. 2000. Acute toxicity to rats and trout with a focus on inhalation and aquatic exposures. Ecotoxicol Environ Saf 46:225-233.
15. Depledge MH. 1998. The ecotoxicological significance of genotoxicity in marine invertebrates. Mutat Res 399:109-122.
16. Eaton DL, Klaassen CD. 2001. Principles of toxicology. In: Klaassen CD, editor. Casarett and Doull's toxicology, the basic science of poisons. 6th ed. New York (NY): McGraw-Hill. p 11-34.
17. [EMEA] European Medicine Agency. 2006. Committee for Medicinal Products for Human Use (CHMP): Guideline on the environmental risk assessment of medicinal products for human use http://www.emea.europa.eu/pdfs/human/swp/ 444700en.pdf.
18. Fent K, Weston AA, Caminada D. 2006. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 76:122-159.
19. Flecknell P. 2002. Replacement, reduction and refinement. ALTEX 19:73-78.
20. Fleeger JW, Carman KR, Nisbet RM. 2003. Indirect effects of contaminants in aquatic ecosystems. Sci Total Environ 317:207-233.
21. Fong PP, Huminski PT, D'Urso LM. 1998. Induction and potentiation of parturition in fingernail clams (Sphaerium striatinum) by selective serotonin re-uptake inhibitors (SSRIs). J Exp Zool 280:260-264.
22. Gundert-Remy U, Sonich-Mullin C. 2002. IPCS Uncertainty and variability: The use of toxicokinetic and toxicodynamic data in risk assessment: An international perspective. Planning Workgroup and Drafting Group (International Program on Chemical Safety's). Sci Total Environ 288:3-11.
23. Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG. 2008. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ Sci Technol 42:5807-5813.
24. Hagger JA, Depledge MH, Oehlmann J, Jobling S, Galloway TS. 2006. Is there a causal association between genotoxicity and the imposex effect? Environ Health Perspect 114(Suppl 1):20-26.
25. Hamscher G, Pawelzick HT, Höper H, Nau H. 2004. Antibiotics in soil: routes of entry, environmental concentrations, fate and possible effects. In: Kümmerer K, editor. Pharmaceuticals in the environment: Sources, fate, effects and risks. 2nd ed. Berlin (DE): Springer-Verlag. p 139-147.
26. Han X, Nabb DL, Yang C-H, Snajdr SI, Mingoia RT. 2009. Liver microsomes and S9 from rainbow trout (Oncorhynchus mykiss): comparison of basal level enzyme activities with rat and determination of xenobiotic intrinsic clearance in support of bioaccumulation assessment. Environ Toxicol Chem 28:481-488.
27. Hardege JD, Duncan J, Ram JL. 1997. Tricyclic antidepressants suppress spawning and fertilization in the zebra mussel, Dreissena polymorpha. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 118:59-64.
28. Holsapple MP, Wallace KB. 2008. Dose response considerations in risk assessment-an overview of recent ILSI activities. Toxicol Lett 180:85-92.
29. Huggett DB, Benson WH, Chipman K, Cook JC, Gray LE, Kinter LB, Meyerhoff RD, Trudeau VL. 2005. Role of mammalian data in determining pharmaceutical responses in aquatic species. In: Williams RT, editor. Human pharmaceuticals: Assessing the impact on aquatic ecosystems. Pensacola (FL): SETAC. p 149-181.
30. Huggett DB, Ericson JF, Cook JC, Williams RT. 2004. Plasma concentrations of human pharmaceuticals as predictors of pharmacological responses in fish. In: Kümmerer K, editor. Pharmaceuticals in the environment: Sources, fate, effects and risks. 2nd ed. Berlin (DE): Springer-Verlag. p 373-386.
31. Hutchinson TH, Ankley GT, Segner H, Tyler CR. 2006. Screening and testing for endocrine disruption in fish-biomarkers as "signposts, " not "traffic lights, " in risk assessment. Environ Health Perspect 114(Suppl 1):106-114.
32. Hutchinson TH, Brown R, Brugger KE, Campbell PM, Holt M, Länge R, McCahon P, Tattersfield LJ, van Egmond R. 2000. Ecological risk assessment of endocrine disruptors. Environ Health Perspect 108:1007-1014.
33. Kenakin T. 2003. A guide to drug discovery: Predicting therapeutic value in the lead optimization phase of drug discovery. Nat Rev Drug Discov 2:429-438.
34. Kinter LB, Valentin J-P. 2002. Safety pharmacology and risk assessment. Fundam Clin Pharmacol 16:175-182.
35. Kleinow KM, Nichols JW, Hayton WL, Mckim JM, Barron MG. 2008. Toxicokinetics in fish. In: Di Giulio RT, Hinton DE, editors. The toxicology of fishes. Boca Raton (FL): CRC. p 55-151.
36. Knowles J, Gromo G. 2003. Target selection in drug discovery. Nat Rev Drug Discov 2:63-69.
37. Köhler HR, Kloas W, Schirling M, Lutz I, Reye AL, Langen JS, Triebskorn R, Nagel R, Schönfelder G. 2007. Sex steroid receptor evolution and signalling in aquatic invertebrates. Ecotoxicology 16:131-143.
38. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
39. Kratochwil NA, Huber W, Müller F, Kansy M, Gerber PR. 2002. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 64:1355-1374.
40. Kurelec B. 1993. The genotoxic disease syndrome. Mar Environ Res 35:341-348.
41. Länge R, Dietrich D. 2002. Environmental risk assessment of pharmaceutical drug substances-conceptual considerations. Toxicol Lett 131:97-104.
42. Lemus JA, Blanco G, Grande J, Arroyo B, Garcia-Montijano M, Martinez F. 2008. Antibiotics threaten wildlife: circulating quinolone residues and disease in avian scavengers. PLoS One 3:e1444.
43. Levine SL, Oris JT. 1999. Noncompetitive mixed-type inhibition of rainbow trout CYP1A catalytic activity by clotrimazole. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 122:205-210.
44. Lipsky MS, Sharp LK. 2001. From idea to market: the drug approval process. J Am Board Fam Pract 14:362-367.
45. Lyytikäinen M, Hirva P, Minkkinen P, Hämäläinen H, Rantalainen AL, Mikkelson P, Paasivirta J, Kukkonen JV. 2003. Bioavailability of sediment-associated PCDD/Fs and PCDEs: Relative importance of contaminant and sediment characteristics and biological factors. Environ Sci Technol 37:3926-3934.
46. Maurer M, Escher BI, Richle P, Schaffner C, Alder AC. 2007. Elimination of beta-blockers in sewage treatment plants. Water Res 41:1614-1622.
47. Milligan SR, Balasubramanian AV, Kalita JC. 1998. Relative potency of xenobiotic estrogens in an acute in vivo mammalian assay. Environ Health Perspect 106:23-26.
48. Mimeault C, Woodhouse AJ, Miao XS, Metcalfe CD, Moon TW, Trudeau VL. 2005. The human lipid regulator, gemfibrozil bioconcentrates and reduces testosterone in the goldfish, Carassius auratus. Aquat Toxicol 73:44-54.
49. Miracle AL, Ankley GT. 2005. Ecotoxicogenomics: linkages between exposure and effects in assessing risks of aquatic contaminants to fish. Reprod Toxicol 19:321-326.
50. Montforts MHMM, Brandt I, Hutchinson TH. 2007. Summary of workshop on environmental assessment of human medicines: development and use of aquatic toxicity data. Drug Inform J 41:203-209.
51. Moscardo E, Maurin A, Dorigatti R, Champeroux P, Richard S. 2007. An optimised methodology for the neurobehavioural assessment in rodents. J Pharmacol Toxicol Methods 56:239-255.
52. Naidoo V, Swan GE. 2009. Diclofenac toxicity in Gyps vulture is associated with decreased uric acid excretion and not renal portal vasoconstriction. Comp Biochem Physiol C Toxicol Pharmacol 149:269-274.
53. Oaks JL, GilbertM, Virani MZ, Watson RT, Meteyer CU, Rideout BA, Shivaprasad HL, Ahmed S, Chaudhry MJ, Arshad M, Mahmood S, Ali A, Khan AA. 2004. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 427:630-633.
54. Owen SF, Giltrow E, Huggett DB, Hutchinson TH, Saye J, Winter MJ, Sumpter JP. 2007. Comparative physiology, pharmacology and toxicology of b-blockers in fish: a critical review. Aquat Toxicol 82: 145-162.
55. Owen SF, Huggett DB, Hutchinson TH, Hetheridge MJ, Kinter LB, Ericson JF, Sumpter JP. 2009. Uptake of propranolol, a cardiovascular pharmaceutical, from water into fish plasma and its effects on growth and organ biometry. Aquat Toxicol 93: 217-224.
56. Pang KS. 2009. Safety testing of metabolites: Expectations and outcomes. Chem Biol Interact 179:45-59.
57. Panter GH, Hutchinson TH, Hurd KS, Sherren A, Stanley RD, Tyler CR. 2004. Successful detection of (anti-)androgenic and aromatase inhibitors in pre-spawning adult fathead minnows (Pimephales promelas) using easily measured endpoints of sexual development. Aquat Toxicol 70:11-21.
58. Purves D, Harvey C, Tweats D, Lumley CE. 1995. Genotoxicity testing: current practices and strategies used by the pharmaceutical industry. Mutagenesis 10:297-312.
59. Raevsky OA. 2004. Physicochemical descriptors in property-based drug design. Mini Rev Med Chem 4:1041-1052.
60. Rang HP, Dale MM, Ritter JM, Moore PK. 2003. Pharmacology. 5th ed. London (UK): Churchill Livingstone. p 797.
61. Rattner BA, Whitehead MA, Gasper G, Meteyer C, Link WA, Taggart MA, Meharg AA, Pattee OH, Pain DJ. 2008. Apparent tolerance of Turkey vultures (Cathartes aura) to the non-steroidal anti-inflammatory drug diclofenac. Environ Toxicol Chem 27:2341-2345.
62. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J. 2008. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7:255-270.
63. Rempel MA, Schlenk D. 2008. Effects of environmental estrogens and antiandrogens on endocrine function, gene regulation, and health in fish. Int Rev Cell Mol Biol 267:207-252.
64. Scott GR, Sloman KA. 2004. The effects of environmental pollutants on complex fish behaviour: integrating behavioural and physiological indicators of toxicity. Aquat Toxicol 68:369-392.
65. Seiler JP. 2002. Pharmacodynamic activity of drugs and ecotoxicology-can the two be connected? Toxicol Lett 131:105-115.
66. Singh I. 1997. Biochemistry of peroxisomes in health and disease. Mol Cell Biochem 167:1-29.
67. Singh SS. 2006. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 7:165-182.
68. Snape JR, Maund SJ, Pickford DB, Hutchinson TH. 2004. Ecotoxicogenomics: the challenge of integrating genomics into aquatic and terrestrial ecotoxicology. Aquat Toxicol 67:143-154.
69. Stichtenoth DO, Frolich JC. 2000. COX-2 and the kidneys. Curr Pharm Design 6: 1737-1753.
70. Sumpter JS. 2007. Environmental effects of human pharmaceuticals. Drug Inform J 41:143-147.
71. Sumpter JP, Johnson AC. 2005. Lessons from endocrine disruption and their application to other issues concerning trace organics in the aquatic environment. Environ Sci Technol 39:4321-4332.
72. Swan GE, Cuthbert R, Quevedo M, Green RE, Pain DJ, Bartels P, Cunningham AA, Duncan N, Meharg AA, Oaks JL, Parry-Jones J, Shultz S, Taggart MA, Verdoorn G, Wolter K. 2006. Toxicity of diclofenac to Gyps vultures. Biol Lett 2: 279-282.
73. Swan G, Naidoo V, Cuthbert R, Green RE, Pain DJ, Swarup D, Prakash V, Taggart M, Bekker L, Das D, Diekmann J, Diekmann M, Killian E, Meharg A, Patra RC, Saini M, Wolter K. 2006. Removing the threat of diclofenac to critically endangered Asian vultures. PLoS Biol 4:e66.
74. Ternes TA, Kreckel P, Mueller J. 1999. Behaviour and occurrence of estrogens in municipal sewage treatment plants-II. Aerobic batch experiments with activated sludge. Sci Total Environ 225:91-99.
75. Tonkens R. 2005. An overview of the drug development process. Physician Exec 31:48-52.
76. Usui T, Masuda H. 1996. Testing for carcinogenicity of pharmaceuticals. J Toxicol Sci 21:475-478.
77. van der Oost R, Beyer J, Vermeulen NPE. 2003. Fish bioaccumulation and biomarkers in environmental risk assessment: a review. Environ Toxicol Pharmacol 13:57-149.
78. Weisbrod AV, Sahi J, Segner H, James MO, Nichols J, Schultz I, Erhardt S, Cowan-Ellsberry C, Bonnell M, Hoeger B. 2008. The state of in vitro science for use in bioaccumulation assessments for fish. Environ Toxicol Chem 28:86-96.
79. Whyte JJ, Jung RE, Schmitt CJ, Tillitt DE. 2000. Ethoxyresorufin-O- deethylase (EROD) activity in fish as a biomarker of chemical exposure. Crit Rev Toxicol 30:347-570.
80. Williams M, Saison CLA, Williams DB, Kookana RS. 2006. Can aquatic distribution of human pharmaceuticals be related to pharmacological data? Chemosphere 65:2253-2259.
81. Williams RT. 2005. Human health pharmaceuticals in the environment-an introduction. In: Williams RT, editor. Human pharmaceuticals: Assessing the impact on aquatic ecosystems. Pensacola (FL): SETAC. p 1-46.
82. Williams RT, Huggett DB, Sager NB. 2003. Human drug development and registration, including an example of how environmental safety is evaluated. In: Williams RT, editor. Human pharmaceuticals: Assessing the impact on aquatic ecosystems. Pensacola (FL): SETAC. p 47-69.
83. Williams TD, Caunter JE, Lillicrap AD, Hutchinson TH, Gillings EG, Duffell S. 2007. Evaluation of the reproductive effects of tamoxifen citrate in partial and full lifecycle studies using fathead minnows (Pimephales promelas). Environ Toxicol Chem 26:695-707.
84. Willmann S, Lippert J, Schmitt W. 2005. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metabol Toxicol 1:159-168.
85. Winter MJ, Lillicrap AD, Caunter JE, Schaffner C, Alder AC, Ramil M, Ternes TA, Giltrow E, Sumpter JP, Hutchinson TH. 2008. Defining the chronic impacts of atenolol on embryo-larval development and reproduction in the fathead minnow (Pimephales promelas). Aquat Toxicol 86:361-369.
86. Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.